In this study, the anti-inflammatory and antioxidant known as lycopene was applied to rats with experimental diabetes with the aim of investigating the detection of diabetes-related complications, and to determine the possible role of lycopene in diabetes complications regarding the effects of ACE activity. In order to induce diabetes in rats in the diabetes (D) and diabetes+lycopene (DL) groups, rats were given 45 mg/kg single-dose streptozotocin (STZ) intraperitoneally (i.p.); lycopene (10 mg/kg/day dissolved in sunflower oil) was administered to the rats in the lycopene-only (L) and DL groups. Blood glucose levels and HbA1c% in diabetes+lycopene group and diabetes group increased (p <0.05) compared to control and only lycopene treated group. The highest level of ACE activity was observed in the (D) group (p < 0.05). Activity in the (L) group was also significantly greater than in the control group (p < 0.05). The (DL) group had lower (p < 0.05). ACE activity than the (D) group. Lycopene implementation was found to be effective in the inhibition of ACE activity, an important indicator of diabetes-related complications.
MolitchME. Diabetes mellitus. In: WalkerHKHallWDHurstJW (eds) Clinical Methods: The History, Physical, and Laboratory Examinations. 3rd edition.Boston: Butterworths, 1990, Chapter 136.
2.
BağrıaçıkN.İ.Ü. Cerrahpaşa Tıp Fakültesi Sürekli Tıp Eğitimi Etkinlikleri, Diabetes mellitus Sempozyumu, İstanbul, 1997, 9–18.
3.
BorodacoA. Classification and diagnosis of diabetes. Terapia2007; 1: 6–11.
4.
ADA (American Diabetes Association) Diagnosis and Classification of diabetes mellitus. Diabetes Care2011; 34(suppl. 1): 62–69.
5.
BrownleeMHirschIB. Glycemic variability: A hemoglobin A1c-ındependent risk factor for diabetic complications. JAMA2006; 295: 1707–1708.
6.
Kurt İ. Glikozile hemoglobin(HbA1c) ölçümü ve diabetes mellitusun uzun dönem glisemik kontrolünde kullanılması. Gülhane Tıp Derg2003; 45: 387–395.
7.
FowlerGCVasudevanDA. Type 2 diabetes mellitus: managing hemoglobin A(1c) and beyond. South Med J2010; 103: 911–916.
8.
MüllerAMGruhnKLangeS. Angiotensin-converting enzyme in the regular pulmonary vasculature. Pathology2004; 25: 141–146.
9.
TurgutS. Anjiotensin dönüştürücü enzim ve I/D polimorfizmi. SDÜ Tıp Fak Derg2005; 12: 53–57.
10.
BaşarYAyalpK. Venöz trombo embolizmin plazma ACE düzeyleri ve ACE gen polimorfizmi ile ilişkisi. Damar Cer Derg2006; 15: 1–6.
11.
GörürA. Tip I Aort Diseksiyonu ve Anjiyotensin Dönüştürücü Converting Enzim (ACE) Gen Polimorfizmi (I/D). Uzmanlık Tezi, İstanbul –2006, Sağlık Bakanlığı, Dr. Siyami Ersek Göğüs Kalp ve Damar Cerrahisi, Eğitim ve Araştırma Hastanesi.
12.
BurnierM. Angiotensin II type 1 receptor blockers. Circulation2001; 103: 904–912.
ÜstündağBÇayMÖzercanİH. Angiotensin-converting enzyme activity in the serum, lung, liver and kidney in streptozotocin-induced diabetic rats and diabetic nephropathy. Tr J Med Sci1998; 28: 231–238.
OostergaMVoorsAde KamP-J. Plasma angiotensin-converting enzyme activity and left ventricular dilatation after myocardial infarction. Circulation1997; 95: 2607–2609.
17.
RubichiniFSteffeninoGDelavalleA. Plasma activity and insertion/deletion polymorphism of angiotensin-I-converting enzyme. Circulation1998; 97: 147–154.
18.
KuznetsovaTStaessenJAWangJG. Antihypertensive treatment modulates the association between the D/I ACE gene polymorphism and left ventricular hypertrophy: a meta-analysis. J Hum Hypertens2000; 14: 447–454.
19.
KardumDHuskicJFabijanicD. Activity of serum angiotensin-converting enzyme as a tumor marker of hepatocellular carcinoma. Eur J Gastroent Hepatol1999; 11: 1209–1213.
20.
HuJMiyatakeFAizuY. Angiotensin-converting enzyme genotype is associated with Alzheimer disease in the Japanese population. Neurosci Let1999; 277: 65–67.
21.
SchernthanerGSchwarzerCKuzmitsR. Increased angiotensin-converting enzyme activities in diabetes mellitus: analysis of diabetes type, state of metabolic control and occurrence of diabetic vascular disease. J Clin Pathol1984; 37: 307–312.
22.
FerrariRCeconiCCurelloS. Cardioprotective effect of angiotensin-converting enzyme inhibitors in patients with coronary artery disease. Cardiovasc Drugs Ther1996; 10(Supp 2): 639–647.
23.
DorganJFSowellASwansonCA. Dose-response effects of lycopene on selected drug-metabolizing and antioxidant enzymes in the rat. Cancer Lett2000; 154: 201–210.
24.
ErhardtJGMeisnerCBodeJC. Lycopene, beta-carotene and colorectal adenomas. Am J Clin Nutr2003; 78: 1219–1224.
25.
BastAHaenenGRVan Den BergR. Antioxidant effects of carotenoids. Int J Vitam Nutr Res1998; 68: 399–403.
26.
CoyneTIbiebeleTIBaadePD. Diabetes mellitus and serum carotenoids: findings of a population-based study in Queensland, Australia. Am J Clin Nutr2005; 82: 685–693.
27.
NeyestaniTRShariatzadehNGharaviA. Physiological dose of lycopene suppressed oxidative stress and enhanced serum levels of immunoglobulin M in patients with type 2 diabetes mellitus: a possible role in the prevention of long-term complications. J Endocrinol Invest2007; 30: 833–838.
PerkinsJMDavisSN. The renin-angiotensin-aldosterone system: a pivotal role in insulin sensitivity and glycemic control. Curr Opin Endocrinol Diabetes Obes2008; 15: 147–152.
30.
BorMVElmaliESAltanN. Serum angiotensin-converting enzyme activity in streptozotocin-induced diabetic rats. Turk J Med Sci2000; 30: 311–314.
31.
ChuKYLeungPS. Angiotensin II in type 2 diabetes mellitus. Curr Protein Pept Sci2009; 10: 75–84.
32.
MarreMBernadetPGalloisY. Relationship between ACE gene polymorphism, plasma levels and diabetic retinal and renal complications. Diabetes1994; 43: 384–389.
33.
FemanSSMericleRAReedGW. Serum angiotensin-converting enzyme in diabetic patients. Am J Med Sci1993; 305: 280–284.
34.
AlfieJAparicioLSWaismanGD. Current strategies to achieve further cardiac and renal protection through enhanced renin-angiotensin-aldosterone system inhibition. Rev Recent Clin Trials2011; 6:134–146.
35.
WatsonAMSoro-PaavonenASheehyK. Delayed intervention with AGE inhibitors attenuates the progression of diabetes-accelerated atherosclerosis in diabetic apolipoprotein E knockout mice. Diabetologia2011; 54: 681–689.
36.
SjølieAKDodsonPHobbsFR. Does renin-angiotensin system blockade have a role in preventing diabetic retinopathy? A clinical review. Int J Clin Pract2011; 65: 148–153.
37.
LiZZLuXZMaCC. Serum lycopene levels in patients with diabetic retinopathy. Eur J Ophthalmol2010; 20: 719–723.
38.
AliMMAghaFG. Amelioration of streptozotocin-induced diabetes mellitus, oxidative stress and dyslipidemia in rats by tomato extract lycopene. Scand J Clin Lab Invest2009; 69: 371–379.
39.
KuhadAChopraK. Lycopene ameliorates thermal hyperalgesia and cold allodynia in STZ-induced diabetic rat. Ind J Exp Biol2008; 46: 108–111.
40.
YüztaşE. The effects of lycopene on prooxidant/total antioxidant status and vitamin levels in experimental diabetic rats. Yüzüncü Yıl University, Health Science Institute, Department of Biochemistry, M.Sci. Thesis, Van, 2011.
